May 16th 2011
The discovery of a new class of compounds has opened the door for healthcare research into drug discovery.
These compounds have been shown to actively and selectively block a large and diverse range of enzymes, meaning they could be used to treat a wide variety of conditions.
Of the 20 compounds which were discovered during the study at the Scripps Research Institute, in Florida, scientists found three which were particularly powerful and had great inhibiting effects.
Compound APEH was found to have the best response against some enzymes, which it inhibited without significantly affecting other enzymes.
Lead author Alexander Adibekian said: "This was unexpected and unusual. But it's what one wants to see with these compounds - strong enzyme-inhibiting activity in different tissues, at a low dose. And it's the first time this kind of evaluation has been done in both cultured cells and animal tissues."
These compounds were judged to have good specificity, meaning they bound to the right enzymes to inhibit their activity and left healthy and useful enzymes to the job they are supposed to do.
Posted by Edward Bartel
1. Adibekian, Alexander. "Click-generated triazole ureas as ultrapotent in vivo–active serine hydrolase inhibitors." Nature Chemical Biology. 15th May 2011.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.